	US 12,076,406 B2
	Conjugates for targeting and clearing aggregates
Damian C. Crowther, Cambridge (GB); Maria Herva, Cambridge (GB); Roland Bürli, Cambridge (GB); and Lutz Jermutus, Cambridge (GB)
Assigned to MEDIMMUNE LIMITED, Cambridge (GB)
Filed by MedImmune Limited, Cambridge (GB)
Filed on Jun. 17, 2021, as Appl. No. 17/350,675.
Application 17/350,675 is a continuation of application No. 16/397,377, filed on Apr. 29, 2019, granted, now 11,065,336.
Claims priority of provisional application 62/664,345, filed on Apr. 30, 2018.
Prior Publication US 2022/0001016 A1, Jan. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/54 (2017.01); A61K 38/10 (2006.01); A61K 47/62 (2017.01); A61P 25/28 (2006.01)

CPC A61K 47/545 (2017.08) [A61K 38/10 (2013.01); A61K 47/62 (2017.08); A61P 25/28 (2018.01)]

24 Claims

1. A conjugate comprising: a) a peptide that competes with an Fc fragment of an IgG for binding to an Fc receptor; and b) a targeting moiety that targets molecular aggregates selected from amyloid, lipid aggregates, polysaccharide aggregates, or glycogen aggregates, wherein the peptide comprises the amino acid sequence of AQVNSCLLLPNLLGC (SEQ ID NO: 2).